(Q51452386)

English

mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.

scientific article published on 28 September 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib. (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

hepatocellular carcinoma

1 reference

based on heuristic

inferred from title

author name string

Wenjun Wang

1

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Wei Bai

2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Enxin Wang

3

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Yan Zhao

4

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Lei Liu

5

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Man Yang

6

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Hongwei Cai

7

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Dongdong Xia

8

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Lei Zhang

9

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Jing Niu

10

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Zhanxin Yin

11

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Zhuoli Zhang

12

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Daiming Fan

13

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Jielai Xia

14

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Guohong Han

15

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

language of work or name

0 references

publication date

28 September 2016

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

International Journal of Cancer

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

140

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

2

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

390-399

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Management of hepatocellular carcinoma: An update

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Clinical decision making and research in hepatocellular carcinoma: pivotal role of imaging techniques

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Response assessment methodologies in hepatocellular carcinoma: complexities in the era of local and systemic treatments

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Treatment of intermediate-stage hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Modified RECIST (mRECIST) assessment for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Skin toxicity predicts efficacy to sorafenib in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Hepatocellular carcinoma: clinical frontiers and perspectives

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Prognostic nomogram for patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FIJC.30451

21 January 2018

Identifiers

10.1002/IJC.30451

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 April 2018

http://europepmc.org/abstract/MED/27681592

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51452386&oldid=2114999374"